Jiwon Oh, MD, PhD, St. Michael's Hospital, University of Toronto, Toronto, Canada, discusses BTK inhibitors (BTKi). BTKi can modulate B-cells, which are known to play a major role in MS pathophysiology. BTKi can also access the central nervous system (CNS) and modulate the innate immune system, including macrophages and microglia, which may contribute to disease progression independent of relapse. A current study is investigating one such BTKi, tolebrutinib, which has shown evidence of CNS penetration. A Phase IIb (NCT03889639) trial reported tolebrutinib was well tolerated over 12 weeks. A long-term extension study (NCT03996291) is now ongoing for those who completed the Phase IIb trial. By 18-months, the efficacy of tolebrutinib was sustained according to MRI and clinical measures, few patients had relapsed, and EDSS scores remained stable. No new safety signals have emerged. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.

свернуть